Risk factors of schizophrenia

Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany

Retrieved on: 
Friday, April 1, 2022
Other Retail, Specialty, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Retail, Agriculture, Natural Resources, Pandemic, NSE, CAGR, Aggression, Bundestag, NYSE, Psychosis, Risk, Wickham Laboratories Ltd, Disease, GMP, Annual report, Education, Security (finance), Purging disorder, Marketing, Spasticity, Dermatology, Laboratory, German Parliament Police, Quality of life, GACP, Industry, Cyprus Securities and Exchange Commission, Vomiting, Agitation, Apathy, Growth, Multimedia, Clinical trial, Mortality, Coronavirus, Epidemic, Risk factors of schizophrenia, BTB, Pain management, BPSD, BSE, Patient, Partnership, Behavior, 25, Group, API, D, BTC, Lists of disasters, EU, Mission statement, CIS, COVID-19, Mediterranean tropical-like cyclone, Depression, Acquisition, RDY, Generic drug, Medical device, Pharmaceutical industry, Dementia

For Dr. Reddy's, the launch reinforces its presence in Germany's growing medical cannabis market, building on its recent acquisition of Nimbus Health GmbH that specializes in the distribution, registration, sales and marketing of medical cannabis.

Key Points: 
  • For Dr. Reddy's, the launch reinforces its presence in Germany's growing medical cannabis market, building on its recent acquisition of Nimbus Health GmbH that specializes in the distribution, registration, sales and marketing of medical cannabis.
  • The demand for medical cannabis has increased over the past years, driven by the German Parliament's (Bundestag) legalization of medical cannabis in 2017.
  • Patrick Aghanian, Head of European Generics, Dr. Reddy's, said: "This collaboration with MediCane Health demonstrates Dr. Reddy's commitment to take a leadership position in Europe's rapidly growing medical cannabis market.
  • With MediCane, we join forces with a unique and differentiated research-based partner in the medical cannabis field.

Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital

Retrieved on: 
Thursday, March 24, 2022
Spinal cord, Private Securities Litigation Reform Act, Company, Therapy, Risk, Neurodegeneration, DRS, Regulus Therapeutics, Microglia, HIV disease progression rates, Multimedia, Lists of diseases, ALS, Oligonucleotide, CNS, Research, Risk factors of schizophrenia, Survival, Toxicology, McGovern Medical School, Hospital, CSO, Associate, ISCB Senior Scientist Award, U.S. Securities and Exchange Commission, Laboratory, MicroRNA, Center, Technology, BWH, CA, COVID-19, Harvard Medical School, Brigham and Women's Hospital, Drug discovery, Founder, SAN, Patient, Disease, Neurology, Security (finance), Pharmaceutical industry, Amyotrophic lateral sclerosis, Regulus

SAN DIEGO, March 24, 2022  /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the initiation of studies evaluating a library of oligonucleotides designed to block miR-155 for the potential to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) under a collaboration agreement with the laboratories of Oleg Butovsky, Ph.D., and Howard L. Weiner, M.D., at Brigham and Women's Hospital (BWH). The agreement, effective since September 2021, encompasses the investigation of the biologic effects of miR-155 inhibitors in both in vitro and in vivo models of ALS.

Key Points: 
  • Dr. Butovsky is an Associate Professor of Neurology at Harvard Medical School and a Senior Scientist at BWH.
  • Results from these initial studies will be used to guide the design of future experiments in additional animal models of the disease and characterize their properties.
  • Butovsky and Weiner, who are leading ALS researchers at Brigham and Women's Hospital, affiliated with Harvard Medical School," commented Denis Drygin, Ph.D., CSO of Regulus Therapeutics.
  • Regulus Therapeutics Inc.(Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.

Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH

Retrieved on: 
Thursday, February 3, 2022
Packaging, Retail, Health, Manufacturing, Supply Chain Management, Online Retail, Pharmaceutical, Transport, Oncology, Other Science, Research, Science, Logistics, Supply Chain Management, Cardiology, CNS, Growth, RDY, Disease, BSE, Patient, Mortality, Wickham Laboratories Ltd, Risk factors of schizophrenia, CIS, Coronavirus, API, Bundestag, Pandemic, Laboratory, Pain management, Lists of disasters, Mission statement, COVID-19, Epidemic, CAGR, German Parliament Police, U.S. Securities and Exchange Commission, Annual report, Health, Acquisition, Industry, Security (finance), 25, NYSE, Dermatology, Risk, Pharmacist, NSE, Generic drug, Medicinal plants, Medical device, Nimbus, Nimbus Health GmbH, Dr. Reddy's, NIMBUS HEALTH GMBH, DR. REDDY'S

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it has entered into a definitive agreement to acquire Nimbus Health GmbH ("Nimbus Health").

Key Points: 
  • Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it has entered into a definitive agreement to acquire Nimbus Health GmbH ("Nimbus Health").
  • Nimbus Health is a privately owned, licensed pharmaceutical wholesaler from Germany focusing on medical cannabis in Germany.
  • Dr. Reddy's will acquire Nimbus Health for an upfront payment plus performance and milestone-based earn-outs over the next four years
    Founded in 2018, Nimbus Health is one of the pioneer companies for medical cannabis in Germany.
  • The demand for medical cannabis has increased over the past years with the legalization of medical cannabis by the German Parliament (Bundestag) in 2017.

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

Retrieved on: 
Monday, July 26, 2021
Geriatrics, Parkinson's disease, Psychiatric diagnosis, Branches of biology, Medicine, Clinical medicine

ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Company's Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration (FDA) has given the Company clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients.

Key Points: 
  • Following the review, the Agency met with the Company on July 22, 2021, and granted the company permission to begin evaluation of IkT-148009 in Parkinson's patients.
  • "The extension of our Phase 1 study of IkT-148009 for the treatment of Parkinson's disease into patients is an important milestone for Inhibikase.
  • Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
  • Inhibikase is currently evaluating the safety, tolerability and pharmacokinetics of IkT-148009in older and healthy subjects and Parkinson's patients.

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

Retrieved on: 
Tuesday, March 2, 2021
Psychiatry, Abnormal psychology, Psychology, Psychopathology, Schizophrenia, Psychosis, Psychiatric diagnosis, Dopamine hypothesis of schizophrenia, Risk factors of schizophrenia

The results from the Phase II INTERACT study are being evaluated to determine next steps for development activities.

Key Points: 
  • The results from the Phase II INTERACT study are being evaluated to determine next steps for development activities.
  • "The Phase II INTERACT study was a well-designed and executed clinical study that resulted in a negative outcome for luvadaxistat on the primary endpoint assessing the change from baseline in negative symptoms of schizophrenia.
  • "The totality of the top-line data from this study therefore support further clinical evaluation of luvadaxistat.
  • These approaches do not impact the negative symptoms of schizophrenia or cognitive impairment associated with schizophrenia (CIAS), suggesting that dysfunction of the dopamine system might not fully explain the negative and cognitive symptoms associated with schizophrenia.